-
ASCO18 Recap: How Immunotherapy is Revolutionizing Cancer Treatment
Our recap of the immunotherapy highlights from the world’s largest clinical cancer conference in 2018
-
ASCO18 Update: Using Biomarkers to Improve Immunotherapy
The final day of ASCO18 focused on biomarkers’ potential to improve immunotherapy as well as the next-generation…
-
ASCO18 Update: Much Ado About Melanoma (and Lung Cancer, Too)
Day 4 of ASCO18 focused on the past, present, and future of melanoma treatment, and also revealed…
-
ASCO18 Update: Immunotherapy Progress in Lung Cancer, New Promise in Ovarian Cancer
Day 3 of ASCO18 revealed more of immunotherapy’s benefits in lung cancer, especially as a first-line option,…
-
ASCO18 Update: Enhancing the Immune System’s Power Through Combination Therapies
Day 2 of ASCO18 highlighted a number of combinations and novel agents that aimed to improve immunotherapy’s…
-
ASCO18 Update: Vaccines, CAR T Cells, and OX40 Checkpoint Therapy
The first day of ASCO18 highlighted diverse immunotherapies, including vaccines, CAR T cells, and novel checkpoint drugs
-
30 Days of CRI Impact
Throughout Cancer Immunotherapy Month in June we’ll be highlighting the 30 most important CRI-funded breakthroughs.
-
ASCO18: Delivering Discoveries – Expanding the Reach of Precision Medicine
The world’s largest clinical cancer conference returns to Chicago June 1-5
-
Second CAR T Cell Immunotherapy Approved for Patients with Lymphoma
A second CAR T cell immunotherapy targeting the CD19 receptor was approved by the FDA for patients…
